Albiglutide is a once-weekly GLP-1 receptor agonist; in the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, cardiovascular death, myocardial infarction or stroke occurred in 7% on albiglutide and 9% on placebo over a median 1.6 years (hazard ratio 0.78).
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Albiglutide' with aliases Tanzeum, Eperzan, Syncria, GSK716155 · 2026-09-27 12:04 · somebody
kind set kind set to protein: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added summary: Albiglutide is a once-weekly GLP-1 receptor agonist; in the Harmony Outcomes trial of 9,463 people with type 2 diabetes · 2026-09-27 12:04 · somebody
fact added summary: In the 32-week HARMONY 7 comparison, once-daily liraglutide lowered HbA1c more than once-weekly albiglutide (-0.99% agai · 2026-09-27 12:04 · somebody
citation added pmid 30291013 cited as established: Albiglutide reduced major cardiovascular events against placebo in type 2 diabetes with cardiovascul · 2026-09-27 12:04 · somebody
citation added pmid 24703047 cited as established: Liraglutide lowered HbA1c more than albiglutide in a head-to-head phase 3 trial (HARMONY 7) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.